Mario Rico Molina

Mr. Mario Rico Molina

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMario Rico Molina
Mario Rico Molina
JOJuan Ortega-Vidal
Juan Ortega-Vidal
JMJuan Molina-Canteras
Juan Molina-Canteras
JCJusto Cobo
Justo Cobo
JAJoaquin Altarejos
Joaquin Altarejos
SSSofia Salido
Sofia Salido
Human lactate dehydrogenase A (hLDHA) is a homotetrameric isozyme involved in the conversion of glyoxylate into oxalate in the cytosol of liver cells (hepatocytes) and partially responsible for the overproduction of oxalate in patients with the rare disease called primary hyperoxaluria (PH). Recently, hLDHA inhibition has been validated as a safe therapeutic method to try to control the PH disease. Stiripentol (STP) is an approved drug used in the treatment of seizures associated with Dravet’s syndrome (a severe form of epilepsy in infancy) which, in addition, has been drawing interest in recent years also for potentially treating PH, due to its hLDHA inhibitory activity. In this work, several new STP-related compounds have been synthesized and their hLDHA inhibitory activity has been compared to that of STP. The synthesis of these analogues to STP was accomplished using crossed-aldol condensation guided by lithium enolate chemistry and a successive regioselective reduction of the resulting α,β-unsaturated ketones. The target molecules were obtained as racemates, which were separated into their enantiomers by chiral HPLC. The absolute configurations of pure enantiomers were determined by the modified Mosher’s method and electronic circular dichroism (ECD) spectroscopy. For the inhibitory effect over the hLDHA catalytic activity, a kinetic spectrofluorometric assay was used. All the new synthesized compounds turned out to be more active at 500 μM (46–72% of inhibition percentage) than STP (10%), which opens a new line of study on the possible capacity of these analogues to reduce urinary oxalate levels in vivo more efficiently.

11 December 2024 in Molbank
Verified
Journal Article
Open access
PDF file
MMMario Rico Molina
Mario Rico Molina
JAJoaquin Altarejos
Joaquin Altarejos
SSSofia Salido
Sofia Salido
The title compound (1) was obtained within a project to synthesize analogs of the antiepileptic drug stiripentol. Compound 1 was synthesized by aldol addition of the lithium enolate of 4-(benzo[d][1,3]dioxol-5-yl)butan-2-one (2) to 3,3-dimethylbutan-2-one (3), followed by the dehydration of the resulting β-hydroxy-ketone under acid processing. The structure of 1 was established by 1D and 2D NMR spectroscopy and high-resolution mass spectrometry.

17 January 2025 in Molbank
Verified
Journal Article
Open access
PDF file
MMMario Rico Molina
Mario Rico Molina
DPDavid Peña-García
David Peña-García
JAJoaquin Altarejos
Joaquin Altarejos
SSSofia Salido
Sofia Salido
The title compound (1) was obtained within a project aimed at synthesizing inhibitors of the human enzyme lactate dehydrogenase A (hLDHA). Compound 1 was synthesized by Suzuki cross-coupling of (E)-1-(4-bromophenyl)-N-(4-methoxyphenyl)methanimine (2a) or (E)-1-(4-iodophenyl)-N-(4-methoxyphenyl)methanimine (2b) with 4-(trifluoromethyl)phenylboronic acid (3) using Pd(PPh3)4 as a catalyst in 86% and 87% yields, respectively. Halo-imines 2a and 2b were previously obtained by condensation reaction between p-anisidine (4) and 4-bromo-benzaldehyde (5a) or 4-iodo-benzaldehyde (5b), respectively. The structure of compound 1 was established by 1D and 2D NMR spectroscopy, infrared and ultraviolet spectroscopies, and high-resolution mass spectrometry.